je.st
news
Tag: patients
PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients
2014-05-13 11:58:44| Logistics - Topix.net
The EVOLVE trial is a phase I/II trial of intravenous administration of enadenotucirev to patients with epithelial cancers and the MoA trial is a phase I "window of opportunity" trial evaluating intravenous and intra-tumoural administration of enadenotucirev to patients with colon cancer.
Tags: results
study
release
cancer
FDA Approves ZONTIVITY (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
2014-05-12 13:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZONTIVITY (vorapaxar) for the reduction of thrombotic cardiovascular events in patients with a history of heart attack (myocardial infarction) or in patients with narrowing of leg arteries, called peripheral arterial disease (PAD). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients
2014-05-08 15:00:00| Merck.com - Research & Development News
Dateline City: WUPPERTAL, Germany & WHITEHOUSE STATION, N.J. WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orAiCurisMedia:Katja Woestenhemke, +49-202-317-63-1176 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
publication
journal
agent
Smartphone Apps to Help Patients Take Their Meds
2014-04-16 21:13:14| Biotech - Topix.net
Several smartphone apps are available to help patients take their medications as prescribed.
Tags: their
patients
apps
smartphone
What cancer's miracle patients can teach us about the disease
2014-04-14 15:53:08| Biotech - Topix.net
Now scientists are starting to use sophisticated DNA sequencing technology to determine if these "exceptional responders" carry gene variations that can lead to new treatment approaches, better targeted therapies or even the re- emergence of experimental drugs once deemed failures.
Tags: the
disease
patients
teach
Sites : [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] next »